UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA ) ) ) ) ) ) ) ) CLASS ACTION

Transcription

1 In re SERACARE LIFE SCIENCES, INC. SECURITIES LITIGATION This Document Relates To: ALL ACTIONS. UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA Master File No. 05-CV-2335-JLS(CAB CLASS ACTION NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS WHO PURCHASED OR OTHERWISE ACQUIRED SERACARE LIFE SCIENCES, INC. ( SERACARE COMMON STOCK BETWEEN MAY 14, 2003 AND MARCH 23, 2006, INCLUSIVE ( CLASS PERIOD PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THIS LITIGATION. PLEASE NOTE THAT IF YOU ARE A CLASS MEMBER, YOU MAY BE ENTITLED TO SHARE IN THE PROCEEDS OF THE SETTLEMENT DESCRIBED IN THIS NOTICE. TO CLAIM YOUR SHARE OF THIS FUND, YOU MUST SUBMIT A VALID PROOF OF CLAIM AND RELEASE POSTMARKED ON OR BEFORE MARCH 30, 2009, if you did not previously submit a valid proof of claim in connection with the previous settlement described below. This Notice has been sent to you pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Southern District of California (the Court. The purpose of this Notice is to inform you of the proposed settlement of this class action litigation and of the hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the settlement. The settlement resolves the remaining claims against CIBC World Markets Corp. ( CIBC, Thomas Weisel Partners LLC ( Weisel, William Blair & Company, LLC ( Blair and KPMG LLP ( KPMG. The Court previously, on September 4, 2007, approved a settlement of the Class s claims against SeraCare, Samuel Anderson, Jerry L. Burdick, Robert J. Cresci, Michael F. Crowley, Jr., Craig A. Hooson, Ezzat Jallad, Dr. Bernard Kasten, Thomas Lawlor, Barry D. Plost, Dr. Nelson Teng and Pecks Management Partners, Ltd. ( Partial Settlement. This Notice describes the rights you may have in connection with the settlement and what steps you may take in relation to the settlement and this class action litigation. This Notice relates to a settlement with defendants CIBC, Weisel, Blair and KPMG. If you submitted a valid Proof of Claim and Release form in connection with the previous settlement with SeraCare (and others in the Litigation, please do not submit another Proof of Claim and Release form. The proposed settlement creates a fund in the amount of $1,600, in cash and will include interest that accrues on the fund prior to distribution. If Class Members owning 100% of the eligible SeraCare shares purchased or acquired during the Class Period elect to participate in this settlement, the estimated distribution per share to Class Members who purchased or acquired SeraCare common stock would be approximately $0.12 before deduction of Court-approved fees and expenses. Historically, actual claim rates are less than 100%, resulting in higher distributions per share. Your actual recovery from this fund will depend on a number of variables, including the number of claimants and amounts of stock they purchased, the number of shares of SeraCare common stock you purchased or acquired, the expense of administering the claims process, and the timing of your purchases and sales, if any (see the Plan of Allocation below for a more detailed description of how the settlement proceeds will be allocated to the Class Members. Lead Plaintiffs and Defendants do not agree on the average amount of damages per share that would be recoverable if Lead Plaintiffs were to have prevailed on each claim asserted. The issues on which the parties disagree include: (1 whether the statements made or facts allegedly omitted were false, material or otherwise actionable under the federal securities laws; (2 the extent to which the various matters that Lead Plaintiffs alleged were materially false or misleading influenced (if at all the trading price of SeraCare common stock at various times during the Class Period; (3 the extent to which the various allegedly adverse material facts that Lead Plaintiffs alleged were omitted influenced (if at all the trading price of SeraCare common stock at various times during the Class Period; (4 the extent to which external factors, such as general market conditions, influenced the trading price of SeraCare common stock at various times during the Class Period; (5 the effect of various market forces influencing the trading price of SeraCare common stock at various times during the Class Period; (6 the amount by which SeraCare common stock was allegedly artificially inflated (if at all during the Class Period; and (7 the appropriate economic model for determining the amount by which SeraCare common stock was allegedly artificially inflated (if at all during the Class Period. Lead Plaintiffs believe that the proposed settlement is a good recovery and is in the best interests of the Class. Because of the risks associated with continuing to litigate and proceeding to trial, there was a danger that Lead Plaintiffs would not have prevailed on any of their claims, in which case the Class would receive nothing from Defendants. For example, the Lead Plaintiffs faced the possibility that all or many of the claims in this case could have been dismissed at summary judgment or

2 trial. Moreover, Defendants motion for reconsideration of the Court s order denying in part and granting in part Defendants motions to dismiss had not been decided at the time of settlement, thus posing the risk that Lead Plaintiffs claims would get dismissed. In addition, the amount of damages recoverable, if any, was and continues to be vigorously challenged by Defendants. If the settlement is approved by the Court, Lead Counsel will apply to the Court for attorney fees of 25% of the settlement proceeds and payment of expenses not to exceed $125,000, both to be paid from the Settlement Fund. If the amount requested by counsel is approved by the Court, the average cost per share would be approximately $0.04. This Notice is not an expression of any opinion by the Court about the merits of any of the claims or defenses asserted by any party in this Litigation or the fairness or adequacy of the proposed settlement. For further information regarding this settlement you may contact: Rick Nelson, Coughlin Stoia Geller Rudman & Robbins LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, Telephone: Please do not call any representative of the Defendants or the Court. I. NOTICE OF HEARING ON PROPOSED SETTLEMENT A settlement hearing (the Settlement Hearing will be held on March 12, 2009, at 1:30 p.m., before the Honorable Janis L. Sammartino, United States District Judge, at the United States District Court for the Southern District of California, in Courtroom 6 of the Edward J. Schwartz U.S. Courthouse, 940 Front Street, San Diego, California. The purpose of the Settlement Hearing will be to determine: (1 whether this settlement of the claims against Defendants should be approved as fair, reasonable, and adequate to each of the Settling Parties; (2 whether the proposed plan to distribute the settlement proceeds (the Plan of Allocation is fair, reasonable, and adequate; (3 whether the application by Lead Counsel for an award of attorney fees and expenses should be approved and the expenses of the Lead Plaintiffs reimbursed; and (4 whether the Litigation should be dismissed with prejudice as against the Defendants. The Court may adjourn or continue the Settlement Hearing without further notice to the Class. II. DEFINITIONS USED IN THIS NOTICE 1. Authorized Claimant means any Class Member whose claim for recovery has been allowed pursuant to the terms of the Stipulation of Settlement ( Stipulation. 2. Claims Administrator means the firm of Gilardi & Co. LLC. 3. Class means all Persons who purchased or otherwise acquired the common stock of SeraCare between May 14, 2003 and March 23, 2006, inclusive. Excluded from the Class are the Defendants, the former and current directors, officers, subsidiaries and affiliates of any Defendant, as well as any person, firm, trust, corporation, officer, director or other individual or entity in which any Defendant has a controlling interest and the legal representatives, affiliates, heirs, successors-in-interest, or assigns of any such excluded party. Also excluded from the Class (solely with respect to the Litigation are those Persons who timely and validly request exclusion from the Class pursuant to this Notice. 4. Class Member or Class Members mean any Person who falls within the definition of the Class as set forth above. 5. Court means the United States District Court for the Southern District of California. 6. Defendants means KPMG LLP, CIBC World Markets Corp., Thomas Weisel Partners LLC, and William Blair & Company, LLC. 7. Lead Counsel means Coughlin Stoia Geller Rudman & Robbins LLP, Jeffrey D. Light and Daniel S. Drosman, 655 West Broadway, Suite 1900, San Diego, CA and Cohen, Milstein, Hausfeld & Toll, P.L.L.C., Steven J. Toll and Andrew N. Friedman, 1100 New York Avenue, N.W., West Tower, Suite 500, Washington, DC Lead Plaintiffs means Richard, Jana, David, John and Lauren Westlund, and Massachusetts State Guaranteed Annuity Fund (now known as New England Carpenters Guaranteed Annuity Fund. 9. KPMG Released Persons means KPMG LLP, all of KPMG s past, present, and future members, member firms, partners, principals, participating principals, national directors, managing or other agents, management personnel, officers, directors, shareholders, administrators, servants, employees, consultants, advisors, insurers, reinsurers, attorneys, accountants, representatives, parent companies, subsidiaries, related entities, divisions, affiliates, predecessors, successors and assigns, along with the heirs, spouses, executors, administrators, personal representatives, insurers, reinsurers, representatives, estates, successors and assigns of any such Persons. 10. Person means an individual, corporation, partnership, limited partnership, limited liability company, association, joint stock company, estate, legal representative, trust, unincorporated association, government or any political subdivision or agency thereof, and any business or legal entity and their spouses, heirs, predecessors, successors, representatives, or assignees. 2

3 11. Plaintiffs Counsel means any counsel who have appeared for any plaintiff in the Litigation. 12. Released Claims shall mean any and all claims, demands, rights, actions, causes of action, liabilities, damages, losses, obligations, judgments, duties, suits, costs, expenses, matters and issues of any kind or nature whatsoever (including, but not limited to, any claims arising under federal, state or foreign statutory or common law, including the federal securities laws and any state statutory disclosure law, claims relating to alleged fraud, breach of any duty, negligence or otherwise, and any claims related to alleged unjust enrichment or self-dealing, known or unknown, contingent or absolute, suspected or unsuspected, disclosed or undisclosed, hidden or concealed, liquidated or unliquidated, matured or unmatured, accrued or unaccrued, apparent or unapparent, by or on behalf of the Lead Plaintiffs or by or on behalf of any other member of the Class, whether individual, direct, class, derivative, representative, legal, equitable, a bankruptcy proof of claim, or any other type or in any other capacity against the Defendants or any Released Person arising out of, based upon, or related to the purchase and/or acquisition of SeraCare common stock during the Class Period and the allegations, acts, events, facts, matters, transactions, occurrences, statements, representations, misrepresentations or omissions, including any benefits received by any Released Person, or disclosures or public statements made in connection with any of the foregoing, including, but not limited to, the accuracy, adequacy and completeness of such disclosures and any alleged breach of fiduciary duties by any Released Person in any capacity (whether as stockholders, directors, committee members, officers, negotiators, offerors, advisors, or otherwise or the aiding and abetting thereof which were or could have been alleged in the Litigation, excepting any claims to enforce the terms and conditions of the settlement. Notwithstanding any other provision in the Stipulation, Released Claims do not include any claim for violation of the Stipulation. 13. SeraCare means SeraCare Life Sciences, Inc. 14. Settlement Fund means the principal amount of One Million Six Hundred Thousand Dollars ($1,600, in cash, to be paid pursuant to paragraph 2.1 of the Stipulation, plus all interest earned thereon. 15. Settling Parties means, collectively, each of the Defendants, and the Lead Plaintiffs on behalf of themselves and each of the Class Members. 16. Underwriter Defendants means CIBC World Markets Corp., Thomas Weisel Partners LLC and William Blair & Company, LLC. 17. Underwriter Released Persons means the Underwriter Defendants, all of the Underwriter Defendants past, present, and future members, member firms, partners, principals, participating principals, national directors, managing or other agents, management personnel, officers, directors, shareholders, administrators, servants, employees, consultants, advisors, insurers, reinsurers, attorneys, accountants, representatives, parent companies, subsidiaries, related entities, divisions, affiliates, predecessors, successors and assigns, along with the heirs, spouses, executors, administrators, personal representatives, insurers, reinsurers, representatives, estates, successors and assigns of any such Persons. III. THE LITIGATION On and after December 22, 2005, six securities class actions were filed in the United States District Court for the Southern District of California on behalf of a class of purchasers of the common stock of SeraCare. On January 19, 2006, the Court entered an Order consolidating all of these cases under the caption entitled In re SeraCare Life Sciences, Inc. Securities Litigation, Master File No. 05-CV-2335-H(CAB (the Litigation. Thereafter, a similar class action entitled Thorpe v. SeraCare Life Sciences, Inc., 06-CV-0080 was filed and later consolidated by Court Order, on April 7, On April 7, 2006 and April 25, 2006, the Court entered Orders appointing Richard, Jana, David, John and Lauren Westlund, and the Massachusetts State Guaranteed Annuity Fund as Lead Plaintiffs pursuant to 15 U.S.C. 78u-4(a(3(B(i and approved their selection of Coughlin Stoia Geller Rudman & Robbins LLP and Cohen, Milstein, Hausfeld & Toll, P.L.L.C. as Lead Counsel. On July 17, 2006, Lead Plaintiffs filed the Consolidated Complaint for Violations of the Federal Securities Laws ( Consolidated Complaint. The Consolidated Complaint alleged violations of 10(b, 20(a and 20(A of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and 11 and 15 of the Securities Act of 1933 on behalf of a class of purchasers of all Persons who purchased or otherwise acquired SeraCare common stock during the period May 14, 2003 through March 23, On April 24, 2007, Lead Plaintiffs and all defendants other than KPMG, CIBC, Weisel and Blair entered into a Stipulation of Partial Settlement. On September 4, 2007, the Honorable Marilyn L. Huff signed the Partial Final Judgment and Order of Dismissal with Prejudice ( Partial Judgment. The Partial Judgment, among other things, approved the settlement of the Class s claims against SeraCare and others, including certain former officers and directors of SeraCare ( Company Defendants, certified a class for settlement purposes only, and found that the settlement was fair, reasonable and adequate and in accordance with Federal Rule of Civil Procedure 23. No Class Member objected to any aspect of the settlement. On December 5, 2006, Defendants moved to dismiss the Consolidated Complaint, with KPMG arguing that the 10(b claim did not meet the Private Securities Litigation Reform Act of 1995 pleading requirements for falsity, scienter and loss 3

4 causation. KPMG and the Underwriter Defendants asserted that Rule 9(b pleading standards applied to plaintiffs 11 claim, which they argued were not met. Defendants also asserted that the affirmative defense of loss causation was established on the face of the Consolidated Complaint, arguing that Lead Plaintiffs did not establish a causal link between the false statements in SeraCare s 2003 and 2004 financial statements and the SeraCare stock decline on December 20, As a result of the settlement, the Company Defendants did not respond to the Consolidated Complaint. After extensive briefing, Defendants motions were granted with leave to amend. On June 1, 2007, Lead Plaintiffs filed the First Amended Consolidated Complaint for Violations of the Federal Securities Laws (the Complaint, which included additional allegations against Defendants. The Complaint attached numerous documents obtained from SeraCare pursuant to the terms of the settlement agreement with the Company Defendants. On July 16, 2007, KPMG and the Underwriter Defendants filed motions to dismiss the Complaint on the same grounds as their motions to dismiss the Consolidated Complaint. On March 14, 2008, the Court entered an order granting in part and denying in part KPMG s motion to dismiss the 11 claims and dismissing the 10(b claims with leave to replead. The Court denied the Underwriter Defendants motion to dismiss. KPMG, joined by the Underwriter Defendants, thereafter filed a Motion for Reconsideration, which was sub judice at the time the Settling Parties agreed to settle the Litigation. IV. CLAIMS OF THE LEAD PLAINTIFFS AND BENEFITS OF SETTLEMENT Lead Plaintiffs believe that the claims asserted in the Litigation have merit and that the evidence developed to date supports those claims. However, the Lead Plaintiffs recognize and acknowledge the expense and length of continued proceedings necessary to prosecute the Litigation against Defendants through trial and through appeals. The Lead Plaintiffs also have taken into account the uncertain outcome and the risk of any litigation, especially in complex actions such as this Litigation, as well as the difficulties and delays inherent in such litigation. Lead Plaintiffs are also mindful of the inherent difficulties of proof under and possible defenses to the securities law violations asserted in the Litigation. Based on their evaluation, Lead Plaintiffs and Lead Counsel have determined that the settlement set forth in the Stipulation is in the best interests of Lead Plaintiffs and the Class. V. DEFENDANTS STATEMENT AND DENIALS OF WRONGDOING AND LIABILITY Defendants expressly have denied and continue to deny all charges of wrongdoing or liability against them arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Litigation. Defendants also continue to believe the claims asserted against them in the Complaint are without merit. Nonetheless, Defendants have agreed to enter into the settlement solely to avoid the expense, distraction, time, and uncertainty associated with continuing the Litigation. The Defendants have concluded that further conduct of the Litigation would be protracted and expensive and that it is desirable that the Litigation be fully and finally settled in the manner and upon the terms and conditions set forth in the Stipulation. The Defendants also have taken into account the uncertainty and risks inherent in any litigation, especially in complex cases such as this Litigation. The Defendants have, therefore, determined that it is desirable and beneficial to them that the Litigation be settled in the manner and upon the terms and conditions set forth in the Stipulation. VI. TERMS OF THE PROPOSED SETTLEMENT The Settlement Fund consists of $1,600, in cash plus interest which will be paid into an escrow account. Of this amount, $800, shall be paid or caused to be paid by KPMG and $800, shall be paid or caused to be paid by the Underwriter Defendants within seven (7 business days of Defendants counsel s receipt of notice of the Court s preliminary approval of the settlement. If the Settlement Fund is not transferred as set forth above, interest will accrue at 8% per annum from the date such payment was due on such portion of the Settlement Fund not transferred, until the date such sums are paid. A portion of the settlement proceeds will be used for certain administrative expenses, including costs of printing and mailing this Notice, the cost of publishing a newspaper notice, payment of any taxes assessed against the Settlement Fund and costs associated with the processing of claims submitted. In addition, as explained below, a portion of the Settlement Fund may be awarded by the Court to Lead Counsel as attorney fees and expenses and to the Lead Plaintiffs for their expenses. The balance of the Settlement Fund (the Net Settlement Fund will be distributed according to the Plan of Allocation described below to Class Members who submit or have previously submitted valid and timely Proof of Claim and Release forms. VII. PLAN OF ALLOCATION The Net Settlement Fund will be distributed to Class Members who submit valid, timely Proof of Claim and Release forms ( Authorized Claimants under the Plan of Allocation described below. The Plan of Allocation provides that you will be eligible to participate in the distribution of the Net Settlement Fund only if you have a net loss on all transactions in SeraCare common stock during the Class Period. 4

5 For purposes of determining the amount an Authorized Claimant may recover under the Plan of Allocation, Lead Counsel have consulted with their damage consultants and the Plan of Allocation reflects an assessment of the damages that could have been recovered as well as Lead Counsel s assessment of the likelihood of establishing liability for various periods of the Class. To the extent there are sufficient funds in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant s claim, as defined below. If, however, the amount in the Net Settlement Fund is not sufficient to permit payment of the total claim of each Authorized Claimant, then each Authorized Claimant shall be paid the percentage of the Net Settlement Fund that each Authorized Claimant s claim bears to the total of the claims of all Authorized Claimants. Payment in this manner shall be deemed conclusive against all Authorized Claimants. The total of all profits shall be subtracted from the total of all losses from transactions during the Class Period to determine if a Class Member has a claim. Only if a Class Member had a net loss, after all profits from transactions in SeraCare common stock during the Class Period are subtracted from all losses, will such Class Member be eligible to receive a distribution from the Net Settlement Fund. A claim shall be calculated as follows. 1. For shares of SeraCare common stock purchased or otherwise acquired from May 14, 2003 through December 19, 2005, and (a sold prior to December 20, 2005, the claim per share is $0; (b sold on or after December 20, 2005 through March 21, 2006, the claim per share is the lesser of: (i the purchase price less the sales price, or (ii $9.26 (December 20, 2005 price decline; (c sold on March 22, 2006, the claim per share is the lesser of: (i the purchase price less the sales price, or (ii $16.93 (December 20, 2005 and March 22, 2006 price declines; (d retained at the end of March 22, 2006, the claim per share is the lesser of: (i the purchase price less $1.75 (March 23, 2006 closing price, or (ii $19.03 (December 20, 2005, March 22, 2006 and March 23, 2006 price declines. 2. For shares of SeraCare common stock purchased or otherwise acquired from December 20, 2005 through March 21, 2006, and (a sold prior to March 22, 2006, the claim per share is $0; (b sold on March 22, 2006, the claim per share is the lesser of: (i the purchase price less the sales price, or (ii $7.67 (March 22, 2006 price decline; (c retained at the end of March 22, 2006, the claim per share is the lesser of: (i the purchase price less $1.75 (March 23, 2006 closing price, or (ii $9.77 (March 22, 2006 and March 23, 2006 price declines. 3. For shares of SeraCare common stock purchased or otherwise acquired on March 22, 2006, and (a sold prior to March 23, 2006, the claim per share is $0; (b retained at the end of March 22, 2006, the claim per share is the lesser of: (i the purchase price less $1.75 (March 23, 2006 closing price, or (ii $2.10 (March 23, 2006 price decline. The date of purchase or sale is the contract or trade date as distinguished from the settlement date. The determination of the price paid per share and the price received per share, shall be exclusive of all commissions, taxes, fees and charges. For Class Members who held shares at the beginning of the Class Period or made multiple purchases, acquisitions or sales during the Class Period, the first-in, first-out ( FIFO method will be applied to such holdings, purchases, acquisitions and sales for purposes of calculating a claim. Under the FIFO method, sales of shares during the Class Period will be matched, in chronological order, first against shares held at the beginning of the Class Period. The remaining sales of shares during the Class Period will then be matched, in chronological order, against shares purchased during the Class Period. A Class Member will be eligible to receive a distribution from the Net Settlement Fund only if such Class Member had a net loss, after all profits from transactions in SeraCare common stock during the Class Period are subtracted from all losses. However, the proceeds from sales of shares which have been matched against shares held at the beginning of the Class Period will not be used in the calculation of such net loss. The Court has reserved jurisdiction to allow, disallow or adjust the claim of any Class Member on equitable grounds. VIII. ORDER CERTIFYING A CLASS FOR PURPOSES OF SETTLEMENT On December 17, 2008, the Court certified a class. The Class is defined above. 5

6 IX. PARTICIPATION IN THE CLASS If you fall within the definition of the Class, you are a Class Member unless you elect to be excluded from the Class pursuant to this Notice. If you do not request to be excluded from the Class, you will be bound by any judgment entered with respect to the settlement in the Litigation against the Defendants whether or not you file a Proof of Claim and Release form. If you are a Class Member, you need do nothing (other than timely file a Proof of Claim and Release form (and only then if you have not already done so in connection with the previous Partial Settlement with SeraCare and others if you wish to participate in the distribution of the Net Settlement Fund. Your interests will be represented by Lead Counsel. If you choose, you may enter an appearance individually or through your own counsel at your own expense. In April 2007, Lead Plaintiffs and SeraCare (along with other defendants, but not including KPMG, Blair, Weisel and CIBC entered into the Partial Settlement which provided for the establishment of a settlement fund in the amount of $3,000, for the benefit of Class Members. In connection with the Partial Settlement, a Notice of Pendency and Proposed Partial Settlement of Class Action dated June 11, 2007 and a Proof of Claim and Release form were mailed to Class Members, among others. IF YOU SUBMITTED A PROOF OF CLAIM AND RELEASE FORM IN CONNECTION WITH THAT PRIOR NOTICE, YOU DO NOT NEED TO SUBMIT ANOTHER. If you are not sure whether you previously submitted a Proof of Claim and Release form, you may call the Claims Administrator at the toll free number below. If you have not previously submitted a Proof of Claim and Release form, you must do so now in order to share in the settlement fund. You may obtain a copy of the Proof of Claim and Release form for this settlement by writing or calling Gilardi & Co. LLC, P.O. Box 990, Corte Madera, CA ( , or you may obtain a copy of the Proof of Claim and Release form at TO PARTICIPATE IN THE DISTRIBUTION OF THE NET SETTLEMENT FUND, YOU MUST TIMELY COMPLETE AND RETURN THE PROOF OF CLAIM AND RELEASE FORM THAT ACCOMPANIES THIS NOTICE UNLESS YOU HAVE ALREADY DONE SO AS DISCUSSED ABOVE. The Proof of Claim and Release form must be postmarked on or before March 30, 2009, and delivered to the Claims Administrator at the address below. Unless the Court orders otherwise, if you do not timely submit a valid Proof of Claim and Release form, you will be barred from receiving any payments from the Net Settlement Fund, but will in all other respects be bound by the provisions of the Stipulation and the Judgment. X. EXCLUSION FROM THE CLASS You may request to be excluded from the Class. To do so, you must mail a written request stating that you wish to be excluded from the Class to: SeraCare Securities Litigation Claims Administrator c/o Gilardi & Co. LLC P.O. Box 990 Corte Madera, CA The request for exclusion must state: (1 your name, address, and telephone number; and (2 all purchases, acquisitions and sales of SeraCare common stock made during the Class Period, including the dates of each purchase, acquisition or sale, and the number of shares purchased, acquired or sold. YOUR EXCLUSION REQUEST MUST BE POSTMARKED ON OR BEFORE FEBRUARY 12, If you submit a valid and timely request for exclusion, you shall have no rights under the settlement, shall not share in the distribution of the Net Settlement Fund, and shall not be bound by the Stipulation or the Judgment. XI. DISMISSAL AND RELEASES If the proposed settlement of the claims against Defendants is approved, the Court will enter a Final Judgment and Order of Dismissal with Prejudice (the Judgment. The Judgment will dismiss the Released Claims with prejudice as to all Defendants, the KPMG Released Persons and the Underwriter Released Persons. The Judgment will provide that all Class Members who have not validly and timely requested to be excluded from the Class shall be deemed to have released and forever discharged all Released Claims (to the extent members of the Class have such claims against Defendants, the KPMG Released Persons and the Underwriter Released Persons. XII. APPLICATION FOR ATTORNEY FEES AND EXPENSES At the Settlement Hearing, Lead Counsel will request the Court to award attorney fees of 25% of the Settlement Fund, plus expenses, not to exceed $125,000, which were incurred in connection with the Litigation, plus interest thereon. In addition, Lead Plaintiffs may also seek payment of their expenses incurred in representing the Class in the Litigation. Class Members are not personally liable for any such fees, expenses or compensation. XIII. CONDITIONS FOR SETTLEMENT The settlement of the Class s claims against the Defendants is conditioned upon the occurrence of certain events described in the Stipulation. Those events include, among other things: (1 entry of the Judgment by the Court, as provided for 6

7 in the Stipulation; and (2 expiration of the time to appeal from or alter or amend the Judgment. If, for any reason, any one of the conditions described in the Stipulation is not met, the Stipulation might be terminated and, if terminated, will become null and void, and the parties to the Stipulation will be restored to their respective positions in the Litigation prior to the settlement. XIV. THE RIGHT TO BE HEARD AT THE HEARING Any Class Member who has not validly and timely requested to be excluded from the Class, and who objects to any aspect of the settlement, the Plan of Allocation, or the application for attorney fees and expenses or payment of the Lead Plaintiffs expenses, may appear and be heard at the Settlement Hearing. Any such Person must submit and serve a written notice of objection, to be received on or before February 26, 2009, by each of the following: COUGHLIN STOIA GELLER RUDMAN & ROBBINS LLP JEFFREY D. LIGHT 655 West Broadway, Suite 1900 San Diego, CA Counsel for KPMG LLP: BINGHAM McCUTCHEN LLP SCOTT VICK th Street, 4th Floor Santa Monica, CA CLERK OF THE COURT UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA 880 Front Street, Suite 4290 San Diego, CA Lead Counsel for Plaintiffs: COHEN, MILSTEIN, HAUSFELD & TOLL, P.L.L.C. ANDREW N. FRIEDMAN 1100 New York Avenue, N.W. West Tower, Suite 500 Washington, DC Counsel for CIBC World Markets Corp., Thomas Weisel Partners LLC and William Blair & Company, LLC: SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP PETER B. MORRISON 300 South Grand Avenue, Suite 3400 Los Angeles, CA The notice of objection must demonstrate the objecting Person s membership in the Class, including the number of shares of SeraCare common stock purchased, acquired and sold during the Class Period, and contain a statement of the reasons for objection. Only Class Members who have submitted written notices of objection in this manner will be entitled to be heard at the Settlement Hearing, unless the Court orders otherwise. XV. SPECIAL NOTICE TO NOMINEES If you, as nominee for a beneficial owner, hold or held any SeraCare common stock purchased or acquired during the Class Period, then, within ten (10 days after you receive this Notice, you must either: (1 request additional copies of the Notice, and, within ten (10 days after the receipt of the additional copies of the Notice, send them by first class mail to all such beneficial owners and send a statement to the Claims Administrator confirming that the mailings were made as directed; or (2 if you have not already done so in connection with the Partial Settlement with SeraCare and others described in the notice dated June 11, 2007, provide a list of the names and addresses of such beneficial owners to the Claims Administrator: SeraCare Claims Administrator c/o Gilardi & Co. LLC P.O. Box 990 Corte Madera, CA If you choose to mail the Notice yourself, you may obtain from the Claims Administrator (without cost to you as many additional copies of these documents as you will need to complete the mailing. Regardless of whether you choose to complete the mailing yourself or elect to have the mailing performed for you, you may obtain reimbursement for, or advancement of, reasonable administrative costs actually incurred or expected to be incurred in connection with forwarding the Notice and Proof of Claim and Release form and which would not have been incurred but for the obligation to forward the Notice and Proof of Claim and Release form, upon submission of appropriate documentation to the Claims Administrator. 7

8 XVI. EXAMINATION OF PAPERS This Notice is a summary and does not describe all of the details of the Stipulation. For full details of the matters discussed in this Notice, you may review the Stipulation filed with the Court, which may be inspected during business hours, at the office of the Clerk of the Court, Southern District of California, 880 Front Street, Suite 4290, San Diego, CA. If you have any questions about the settlement of the Litigation, you may contact Lead Counsel: COUGHLIN STOIA GELLER RUDMAN & ROBBINS LLP c/o Rick Nelson, Shareholder Relations 655 West Broadway, Suite 1900 San Diego, CA COHEN, MILSTEIN, HAUSFELD & TOLL, P.L.L.C. ANDREW N. FRIEDMAN 1100 New York Avenue, N.W. West Tower, Suite 500 Washington, DC PLEASE DO NOT TELEPHONE THE COURT REGARDING THIS NOTICE DATED: December 17, 2008 BY ORDER OF THE COURT UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA 8